Cartesian Therapeutics Q3 net loss narrows 68% to $11.47 million
RNAC•Cartesian Therapeutics' third-quarter 2026 net loss narrowed 68% year over year to $11.47 million. It reported $124.7 million in cash, cash equivalents and restricted cash, expected to support planned operations into 2028.
1. Quarterly results and outlook
Cartesian Therapeutics' third-quarter net loss narrowed 68% year over year to $11.47 million, while research and development expenses rose 13% to $15.62 million, primarily due to higher AURORA and TRITON trial expenses. The company had $124.7 million in cash, cash equivalents and restricted cash at September 30, 2026, which it expects to support planned operations into 2028; Phase 3 AURORA data for Descartes-08 are expected in the first quarter of 2027, with a biologics license application planned for mid-2027.
